文献速递淋巴瘤

GATA6过表达诱导的CD137配体异常表达促进皮肤T细胞淋巴瘤肿瘤进展

Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
PubMed 文献 · Blood · 2018-09-07

本研究探讨CD137L与CD137在皮肤T细胞淋巴瘤(CTCL)中的作用,以蕈样肉芽肿和Sézary综合征为代表。流式细胞术显示原代Sézary细胞及CTCL细胞系(Hut78、MyLa、HH、SeAx、MJ)异常表达CD137L,免疫组化亦证实。抗CD137L中和抗体通过抑制AKT、ERK1/2、p38 MAPK和JNK磷酸化,抑制CTCL细胞系增殖、存活、CXCR4介导的迁移及体内生长,并降低抗凋亡蛋白Bcl-2和磷酸化Bad。DNA低甲基化和组蛋白乙酰化诱导GATA6过表达,GATA6直接上调CD137L表达;抑制GATA6导致CTCL细胞存活和体内生长下降。

要点

  • 原代Sézary细胞和多种CTCL细胞系异常表达CD137L,免疫组化证实肿瘤细胞表达CD137L。
  • 抗CD137L中和抗体抑制CTCL细胞系增殖、存活、CXCR4介导迁移及体内生长。
  • GATA6通过DNA低甲基化和组蛋白乙酰化过表达,直接上调CD137L;抑制GATA6降低CTCL细胞存活和体内生长。

核心结论

  • GATA6/CD137L轴在CTCL肿瘤发生中起重要作用,提示基于该轴的新型治疗方向。

研究设计与样本

  • 研究使用原代Sézary细胞和CTCL细胞系(Hut78、MyLa、HH、SeAx、MJ),采用流式细胞术、免疫组化、抗CD137L中和抗体、染色质免疫沉淀、荧光素酶报告基因 assay 和短发夹RNA敲低等方法。

主要发现

  • 流式细胞术显示原代Sézary细胞和CTCL细胞系(Hut78、MyLa、HH、SeAx、MJ)异常表达CD137L,免疫组化证实CTCL肿瘤细胞表达CD137L。
  • 抗CD137L中和抗体通过抑制AKT、细胞外信号调节激酶1/2、p38 MAPK和JNK磷酸化,抑制CTCL细胞系增殖、存活、CXCR4介导的迁移和体内生长。
  • 抑制CD137L信号降低抗凋亡蛋白Bcl-2和磷酸化Bad。
  • DNA低甲基化和组蛋白乙酰化诱导CTCL细胞GATA6过表达,染色质免疫沉淀、荧光素酶报告基因 assay 和短发夹RNA敲低显示GATA6直接上调CD137L表达。
  • 抑制GATA6导致CTCL细胞存活和体内生长下降。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD137 and its ligand, CD137L, are expressed on activated T cells and antigen-presenting cells, respectively. Recent studies have shown that CD137L and CD137 are aberrantly expressed by tumor cells, especially in some hematopoietic malignancies, and interactions between these molecules on tumor cells promote tumor growth. In this study, we investigated the roles of CD137L and CD137 in cutaneous T-cell lymphoma (CTCL), represented by mycosis fungoides and Sézary syndrome. Flow cytometric analysis showed that primary Sézary cells and CTCL cell lines (Hut78, MyLa, HH, SeAx, and MJ) aberrantly expressed CD137L. CD137L expression by tumor cells in CTCL was also confirmed by immunohistochemistry. Anti-CD137L-neutralizing antibody inhibited proliferation, survival, CXCR4-mediated migration, and in vivo growth in CTCL cell lines through inhibition of phosphorylation of AKT, extracellular signal-regulated kinase 1/2, p38 MAPK, and JNK. Moreover, suppression of CD137L signaling decreased antiapoptotic proteins Bcl-2 and phosphorylated Bad. We also explored the transcription factor regulating CD137L expression. Because GATA6 has been proposed as an oncogene in many types of tumors with aberrant CD137L expression, we examined GATA6 expression and the involvement of GATA6 in CD137L expression in CTCL. DNA hypomethylation and histone acetylation induced GATA6 overexpression in CTCL cells. Furthermore, chromatin immunoprecipitation, luciferase reporter assay, and knockdown by short hairpin RNA showed that GATA6 directly upregulated CD137L expression. Inhibition of GATA6 resulted in decreased survival and in vivo growth in CTCL cells. Collectively, our findings prompt a novel therapeutic approach to CTCL based on the discovery that the GATA6/CD137L axis plays an important role in the tumorigenesis of CTCL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kamijo H, Miyagaki T, Shishido-Takahashi N, et al. Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma. Blood. 2018. PMID: 30194255. doi:10.1182/blood-2018-04-845834

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。